SP100 and primary biliary cholangitis: Our findings confirm and expand upon previous observations, as we discovered that the presence of anti-sp100 antibodies was associated with liver-related adverse outcomes in PBC patients who also had the metabolic risk factor of hypertension at baseline, as shown by univariate analysis.